酪氨酸激酶抑制剂治疗慢性粒细胞白血病后发生的与人类疱疹病毒8无关的原发性渗出性淋巴瘤样淋巴瘤。
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
作者信息
Kojima Minoru, Nakamura Naoya, Amaki Jun, Numata Hiroki, Miyaoka Masashi, Motoori Tadashi, Matsumoto Koshi, Ando Kiyoshi
机构信息
Department of Hematology, Ebina General Hospital.
Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine.
出版信息
J Clin Exp Hematop. 2017;57(2):69-73. doi: 10.3960/jslrt.17020.
Abstract
A 69-year-old man was diagnosed with chronic myelogenous leukemia (CML) and treated with dasatinib. After two years on dasatinib, the patient achieved complete molecular response, but dasatinib treatment was discontinued due to exacerbation of pleural effusion. Nilotinib and imatinib were started but stopped due to an increase in pleural effusion. Thoracentesis was performed and he was diagnosed with human herpesvirus 8-unrelated primary effusion lymphoma (PEL)-like lymphoma. Complex chromosomal abnormality, including BCL6 rearrangement, was found on chromosome analysis. To the best of our knowledge, this is the first report of PEL-like lymphoma following tyrosine kinase inhibitor treatment for CML.
摘要
一名69岁男性被诊断为慢性粒细胞白血病（CML），并接受达沙替尼治疗。使用达沙替尼两年后，患者达到完全分子反应，但由于胸腔积液加重而停用达沙替尼。随后开始使用尼洛替尼和伊马替尼，但因胸腔积液增加而停药。进行了胸腔穿刺术，他被诊断为人疱疹病毒8无关的原发性渗出性淋巴瘤（PEL）样淋巴瘤。染色体分析发现了包括BCL6重排在内的复杂染色体异常。据我们所知，这是酪氨酸激酶抑制剂治疗CML后发生PEL样淋巴瘤的首例报告。
相似文献
1
Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.酪氨酸激酶抑制剂治疗慢性粒细胞白血病后发生的与人类疱疹病毒8无关的原发性渗出性淋巴瘤样淋巴瘤。
J Clin Exp Hematop. 2017;57(2):69-73. doi: 10.3960/jslrt.17020.
2
Dasatinib-related effusion lymphoma in a patient treated for chronic myeloid leukaemia.一名接受慢性髓性白血病治疗的患者发生了与达沙替尼相关的渗出性淋巴瘤。
Cytopathology. 2020 Nov;31(6):602-606. doi: 10.1111/cyt.12890. Epub 2020 Aug 9.
3
Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.达沙替尼治疗的慢性髓性白血病合并 HIV 阴性原发性渗出性淋巴瘤。
Pathobiology. 2023;90(5):356-364. doi: 10.1159/000530429. Epub 2023 Mar 30.
4
Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.在使用达沙替尼治疗慢性髓性白血病期间，出现了一种人类疱疹病毒 8 阴性的积液相关性淋巴瘤。
J Clin Exp Hematop. 2023 Mar 28;63(1):43-48. doi: 10.3960/jslrt.22041. Epub 2023 Mar 26.
5
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.达沙替尼：一种用于治疗慢性粒细胞白血病和费城染色体阳性急性淋巴细胞白血病的酪氨酸激酶抑制剂。
Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.
6
HHV8-negative primary effusion-based large B-cell lymphoma in a patient with chronic myeloid leukemia, BCR::ABL1-positive under dasatinib treatment: Report of a new case and literature review.慢性髓性白血病、达沙替尼治疗下 BCR::ABL1 阳性患者中 HHV8 阴性原发性渗出性大 B 细胞淋巴瘤：新病例报告及文献复习。
Diagn Cytopathol. 2022 Dec;50(12):E351-E356. doi: 10.1002/dc.25027. Epub 2022 Aug 2.
7
Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors.尼洛替尼治疗慢性髓性白血病相关的严重胸腔积液：与酪氨酸激酶抑制剂的交叉不耐受。
BMJ Case Rep. 2021 Sep 3;14(9):e243671. doi: 10.1136/bcr-2021-243671.
8
Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib.伴有抗RNP/Sm及抗核抗体阳性的狼疮样症状：达沙替尼一种极其罕见的不良事件。
J Oncol Pharm Pract. 2020 Apr;26(3):738-741. doi: 10.1177/1078155219863469. Epub 2019 Jul 30.
9
Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.博舒替尼用于达沙替尼治疗期间发生胸腔积液的慢性期慢性粒细胞白血病患者的疗效和安全性
Ann Hematol. 2019 Nov;98(11):2609-2611. doi: 10.1007/s00277-019-03802-y. Epub 2019 Sep 16.
10
Spontaneous regression of dasatinib-related primary effusion lymphoma-like lymphoma.达沙替尼相关性原发性渗出性淋巴瘤样淋巴瘤的自发消退。
Int J Hematol. 2023 Jan;117(1):137-142. doi: 10.1007/s12185-022-03449-y. Epub 2022 Sep 6.
引用本文的文献
1
Cavity-based lymphomas: challenges and novel concepts. A report of the 2022 EA4HP/SH lymphoma workshop.基于腔隙的淋巴瘤：挑战与新观念。2022 年 EA4HP/SH 淋巴瘤研讨会报告。
Virchows Arch. 2023 Sep;483(3):299-316. doi: 10.1007/s00428-023-03599-2. Epub 2023 Aug 9.
2
Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.在使用达沙替尼治疗慢性髓性白血病期间，出现了一种人类疱疹病毒 8 阴性的积液相关性淋巴瘤。
J Clin Exp Hematop. 2023 Mar 28;63(1):43-48. doi: 10.3960/jslrt.22041. Epub 2023 Mar 26.
3
Human herpesvirus 8-negative effusion-based large B-cell lymphoma: a distinct entity with unique clinicopathologic characteristics.人类疱疹病毒 8 阴性渗出液型大 B 细胞淋巴瘤：一种具有独特临床病理特征的独特实体。
Mod Pathol. 2022 Oct;35(10):1411-1422. doi: 10.1038/s41379-022-01091-x. Epub 2022 May 13.
4
HHV8-Negative Effusion-Based Large B Cell Lymphoma Arising in Chronic Myeloid Leukemia Patients under Dasatinib Treatment: A Report of Two Cases.达沙替尼治疗的慢性髓性白血病患者中出现的基于HHV8阴性积液的大B细胞淋巴瘤：两例报告
Biology (Basel). 2021 Feb 14;10(2):152. doi: 10.3390/biology10020152.
5
Primary human herpesvirus 8-negative effusion-based lymphoma: a large B-cell lymphoma with favorable prognosis.原发性人疱疹病毒8阴性渗出性淋巴瘤：一种预后良好的大B细胞淋巴瘤。
Blood Adv. 2020 Sep 22;4(18):4442-4450. doi: 10.1182/bloodadvances.2020002293.
本文引用的文献
1
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.伊马替尼治疗慢性髓性白血病的长期疗效
N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.
2
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.EUTOS 基于人群注册研究中 2904 例 CML 患者的治疗和结局。
Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.
3
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.DASISION的5年最终研究结果：达沙替尼与伊马替尼治疗初治慢性髓性白血病患者的试验
J Clin Oncol. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. Epub 2016 May 23.
4
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.博舒替尼对比伊马替尼用于新诊断的慢性期慢性髓性白血病：来自 BELA 试验的结果。
J Clin Oncol. 2012 Oct 1;30(28):3486-92. doi: 10.1200/JCO.2011.38.7522. Epub 2012 Sep 4.
5
Imatinib mesylate directly impairs class switch recombination through down-regulation of AID: its potential efficacy as an AID suppressor.甲磺酸伊马替尼通过下调 AID 直接损害类别转换重组：作为 AID 抑制剂的潜在疗效。
Blood. 2012 Mar 29;119(13):3123-7. doi: 10.1182/blood-2011-01-327932. Epub 2012 Feb 14.
6
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications.2008 年世界卫生组织淋巴造血组织肿瘤分类及以后：不断发展的概念和实际应用。
Blood. 2011 May 12;117(19):5019-32. doi: 10.1182/blood-2011-01-293050. Epub 2011 Feb 7.
7
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.达沙替尼与伊马替尼治疗新诊断的慢性期慢性髓性白血病。
N Engl J Med. 2010 Jun 17;362(24):2260-70. doi: 10.1056/NEJMoa1002315. Epub 2010 Jun 5.
8
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.尼洛替尼与伊马替尼用于治疗新诊断的慢性髓性白血病。
N Engl J Med. 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5.
9
PEL and HHV8-unrelated effusion lymphomas: classification and diagnosis.原发性渗出性淋巴瘤及与人类疱疹病毒8型无关的渗出性淋巴瘤：分类与诊断
Cancer. 2008 Aug 25;114(4):225-7. doi: 10.1002/cncr.23597.
10
KSHV/HHV8-associated lymphomas.卡波西肉瘤相关疱疹病毒/人疱疹病毒8型相关淋巴瘤
Br J Haematol. 2008 Jan;140(1):13-24. doi: 10.1111/j.1365-2141.2007.06879.x. Epub 2007 Nov 7.
Zotero 插件